Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial. - Wikidata - awgldk - TriplyDB

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.

http://www.wikidata.org/entity/Q37174690

about

New agents on the horizon in gastric cancer.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.Angiogenesis inhibitors in early development for gastric cancer.Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Radical Gastrectomy: Still the Cornerstone of Curative Treatment for Gastric Cancer in the Perioperative Chemotherapy Era-A Single Institute Experience over a Decade.Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.

P2860

Q38759129-524F56C9-F7AA-4FD0-8FCA-62B22A034DAF Q39067386-CBC93A27-CDA9-42D1-A7D5-FE8B7EA63704 Q47218543-2100E039-9114-4B54-BA91-75A1FB646D6C Q47996955-D67A8617-3B4E-43FA-93FB-9AFF6E6DD243 Q48569564-F0719EC6-EC55-47BB-9DB8-4F19C18F0F01 Q55190117-C3C309EB-1B9C-42C5-A3AC-C30B90C651B9 Q55286343-2458915C-119D-4412-9CC4-0830C1014EDE Q55654316-2EC98E72-FC0E-4D8D-A49E-61888C3EC5C2

P2860

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.

http://www.wikidata.org/entity/Q37174690

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@en

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@nl

type

label

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@en

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@nl

prefLabel

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@en

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@nl

P1433

Q37174690-00F44CE0-26D3-44A3-9099-E852571106E1

P1476

Q37174690-872CC627-C52C-42BB-B3FD-E59D4A9D527B

P2093

Q37174690-00C8B169-CF40-4A7A-BD41-EE9C64A8BE6E

Q37174690-0A3FE0B0-ACE6-44F5-AD71-8D3E24B52C2A

Q37174690-104831AC-D40F-4AF6-A449-15616B96EE12

Q37174690-6ABA474A-9F15-4F47-8D90-0558965F5003

Q37174690-75FB5ECE-BE75-405B-8FCB-7D8A1BCD3930

Q37174690-908E52CE-9B1C-4E9D-AD47-09DD60137495

Q37174690-BC43F40C-FD52-4D90-A44B-CDFC131BDFB3

Q37174690-CD0D7D1C-DF92-4748-A68B-418E6AE91AF2

Q37174690-E49C347E-1CFF-451C-8AFF-220C0104BE32

Q37174690-F25EBC05-762D-4F1F-AB48-5DA9EE3CCA8C

P2860

Q37174690-038FF709-616D-46EB-AF60-A8C941FF3D89

Q37174690-09868633-DBDB-424E-A69C-DA527036B866

Q37174690-0E974D15-4EB4-4376-8423-0786B578FA40

Q37174690-2121DEF7-B840-4ABA-9421-F8D7EF14C0D3

Q37174690-22D6FB36-FA76-4516-9B6F-D039CAC217E5

Q37174690-36FD7BCA-52F9-4F45-BF8F-8C32DD35174A

Q37174690-381968A8-0A91-48D0-935D-8145D19E7B6C

Q37174690-3BEBDFE9-DB44-43FA-9063-951554A38CEE

Q37174690-3FC920AD-3D31-4A9B-9B1F-EA013D552290

Q37174690-42BF9244-22D5-4365-9441-AEDD84FCEF41

P2888

Q37174690-C3443ADF-454B-42ED-9ABE-52245F648884

P304

Q37174690-90005569-9194-4165-BCAA-61A98EE4330C

P31

Q37174690-8431A953-5551-4835-AB31-B18D14EAEE39

P356

Q37174690-23F0736F-94F0-4295-9449-028634D3E7B8

P407

Q37174690-6ED68736-7ADB-4194-8DA0-0218C3867282

P433

Q37174690-7E8BED93-E585-4A63-A85E-2938C19F09C1

P478

Q37174690-28DA4F33-F746-4426-A74F-EA5505C43CB8

P50

Q37174690-586040ED-4F55-459D-B414-9E89337FDA84

P577

Q37174690-06139FC8-11F4-4FBA-A703-395AA907AF95

P698

Q37174690-86A72B30-B9E4-49E4-9096-13389FE8B5F4

P921

Q37174690-71BE7F84-65D5-4ED3-9E33-E090404B5A97

Q37174690-E6E85876-7F72-45F9-814A-1B85564DDBB1

P932

Q37174690-1DA6149F-B4D0-43AB-91E8-6C426E449258

P356

P1433

British Journal of Cancer

P1476

Evaluation of Angiopoietin-2 a ...... mised phase III AVAGAST trial.

@en

P2093

Eric Van Cutsem

http://www.w3.org/2001/XMLSchema#string

Hildegard Büning

http://www.w3.org/2001/XMLSchema#string

Lars Schiffmann

http://www.w3.org/2001/XMLSchema#string

Laura Escalona-Espinosa

http://www.w3.org/2001/XMLSchema#string

Nicola Consalvo

http://www.w3.org/2001/XMLSchema#string

Oliver Coutelle

http://www.w3.org/2001/XMLSchema#string

Priti Hedge

http://www.w3.org/2001/XMLSchema#string

Stefan J Scherer

http://www.w3.org/2001/XMLSchema#string

Ulrich T Hacker

http://www.w3.org/2001/XMLSchema#string

Valentin Goede

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Epidemiology of Stomach Cancer

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

Comprehensive molecular characterization of gastric adenocarcinoma

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.

Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway

P2888

P304

855-862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.30

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27031850

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4984795

http://www.w3.org/2001/XMLSchema#string